ReShape Lifesciences Review

Overview

ReShape Lifesciences (formerly ReShape Medical) is a Minnesota-based medical weight management company that occupies a niche no other telehealth platform does: combining an FDA-cleared intragastric balloon procedure with telehealth-based GLP-1 medication management. Founded around 2012 as a device company focused on the non-surgical ReShape Balloon, the company has evolved its model over time to include pharmaceutical weight management alongside its procedural offerings.

As of April 2026, ReShape remains one of the few companies that can offer patients a continuum of non-surgical weight management options — from GLP-1 prescriptions managed remotely to an in-person intragastric balloon placement at affiliated surgical centers. This positions it for patients who want a procedural option without going under general anesthesia, or who are exploring all non-surgical avenues before committing to bariatric surgery.

Important note on program availability: ReShape's business model has evolved significantly since its founding. Before starting any intake process, verify that the GLP-1 telehealth program is currently active and accepting new patients at reshapelifesciences.com. ReShape has a smaller public footprint than major GLP-1 platforms; independent reviews and third-party coverage are limited.

April 2026 regulatory context: The FDA's enforcement actions against compounded GLP-1 medications — specifically compounded semaglutide and tirzepatide — apply to any platform that prescribes compounded versions. If ReShape's telehealth program includes compounded GLP-1s, patients should confirm their pharmacy is operating in compliance with current FDA guidance before filling a prescription.

Medications Offered

ReShape's intragastric balloon (the ReShape Balloon) is FDA-cleared for adults with a BMI of 30–40 who have not responded to diet and exercise alone. It is placed endoscopically and removed after approximately six months.

For the telehealth GLP-1 component, available medications likely include semaglutide and/or tirzepatide. Verify the current formulary — including whether branded (Ozempic, Wegovy, Mounjaro, Zepbound) or compounded versions are offered — directly at reshapelifesciences.com.

Orforglipron (the first oral GLP-1 receptor agonist) has not yet received FDA approval as of April 2026 (PDUFA date: April 10, 2026) and is not available through any telehealth platform.

Pricing

Procedural pricing for intragastric balloons is typically not covered by insurance and must be paid out of pocket. GLP-1 telehealth pricing is not publicly confirmed — verify at reshapelifesciences.com.

States Served

ReShape's telehealth component is likely limited to states where its licensed physicians are authorized to prescribe. The intragastric balloon procedure requires an affiliated surgical center. Verify state availability for both services at reshapelifesciences.com.

Insurance

Insurance does not typically cover intragastric balloon procedures. GLP-1 insurance coverage depends on the specific medication, your plan, and your diagnosed indication. Verify insurance acceptance at reshapelifesciences.com.

Consultation Process

1. Visit reshapelifesciences.com and complete the online intake form.
2. Indicate whether you are interested in the telehealth GLP-1 program, the intragastric balloon, or both.
3. A care coordinator or clinician reviews your health history and BMI.
4. For GLP-1 telehealth: a licensed provider reviews your case asynchronously or via video and, if appropriate, sends a prescription to a pharmacy.
5. For the balloon procedure: you are matched with an affiliated surgical center for an in-person consultation and scheduling.
6. Ongoing care and follow-up vary by track — confirm cadence at intake.

Pros

• Only platform combining telehealth GLP-1 prescribing with an FDA-cleared intragastric balloon option
• Procedural track appeals to patients who prefer a device-based intervention over daily or weekly injections
• Balloon option does not require general anesthesia and is reversible

Cons

• Intragastric balloon procedures cost $3,000–$9,000+ and are rarely covered by insurance
• Smaller platform with limited independent reviews and less public transparency than major GLP-1 telehealth companies
• GLP-1 telehealth program availability and details are difficult to verify independently — confirm before investing time in intake
• Geographic availability for balloon procedures is limited to affiliated surgical centers

Best For

Patients with a BMI of 30–40 who want to explore non-surgical procedural weight management (intragastric balloon) alongside or instead of GLP-1 medication, and who are comfortable engaging with a smaller, less-reviewed platform. Also suitable for patients who have tried GLP-1 medications and want to evaluate a device-based option.

Editorial Verdict

ReShape Lifesciences fills a genuine gap in the weight management landscape by pairing telehealth GLP-1 prescribing with an FDA-cleared intragastric balloon. That differentiation is real and meaningful for the right patient. However, the platform's limited public footprint, evolving business model, and the procedural cost burden make it difficult to recommend broadly without direct verification. If the balloon option is specifically what you're evaluating, ReShape is worth a consultation — but confirm program status and pricing at reshapelifesciences.com before proceeding.

Related Content

• How Much Does Semaglutide Cost?
• How Much Does Tirzepatide Cost?
• Who Qualifies for GLP-1 Medications?